Schrödinger will be responsible for lead optimization drug discovery design, and Otsuka will be responsible for all other drug discovery and clinical development activities.
Japanese company Otsuka Pharmaceutical has announced that the company and its UK-based subsidiary Astex Pharmaceuticals will collaborate with Schrödinger, Inc. on drug discovery research in the area of central nervous system (CNS) diseases. . A large platform with extensive knowledge and expertise of Otsuka Pharmaceutical and Astex in structural biology, including the field of central nervous system diseases.
Under the terms of the agreement, Schrödinger will be responsible for drug design through lead optimization and Otsuka will be responsible for all other drug discovery and clinical development activities, with the aim of rapidly expanding Otsuka’s R&D pipeline. . Schrödinger receives an upfront payment and is eligible to receive tiered royalties on the net sales of products resulting from discovery, development, regulatory milestones and collaborations in all markets.
Toshiki Sudo, Managing Researcher and Director of the Osaka Drug Discovery Research Center, Otsuka Pharmaceutical, said, “Otsuka Pharmaceutical continues to take on the challenge of developing innovative products with unique ideas and technologies to contribute to the health of people around the world. By combining our drug discovery capabilities and extensive drug discovery experience with Schrödinger’s digital drug discovery technology and structural analysis technology using cryo-electron microscopy, we will work to solve unmet medical needs through the creation of innovative drugs. I’ll go.”